EL-13· Research peptide
SS-31
Batch analytics · >99 % purity
Illustrative image; appearance and packaging may vary. 10 unlabelled vials, labelled only on the kit packaging. The selected strength applies.
EL-13· Research peptide
Batch analytics · >99 % purity
Illustrative image; appearance and packaging may vary. 10 unlabelled vials, labelled only on the kit packaging. The selected strength applies.
Tier I · Synthesis QC
Tier I · Synthesis QC
In-house · per step
RP-HPLC, MS confirmation, sequence verification in cleanroom.
Tier II · In-process
953
satisfied
99.41%
Avg. purity 2026
4.8 ★
Store rating
EL-13 · Reference data
Mitochondrien-zielendes Tetrapeptid
Aliases: Elamipretide · Bendavia
SS-31, also known internationally as elamipretide, is a tetrapeptide made up of four amino acids. Its sequence D-Arg-dimethylTyr-Lys-Phe-NH2 combines a cationic structural framework with aromatic side chains; the amidated C-terminus and the net charge of +3 shape its physicochemical profile. It is this very combination that makes the molecule interesting for mitochondrial research, because it enables a directed interaction with the inner mitochondrial membrane.
Cardiolipin is an anionic phospholipid of the inner mitochondrial membrane. It shapes the cristae structure, the folded invaginations of this membrane, and supports the spatial organization of the respiratory chain complexes. Cardiolipin thus connects membrane architecture with the energy conversion of mitochondria.
The cristae enlarge the inner membrane surface and host a large proportion of the respiratory chain complexes. Their organization allows electron transport and ATP synthesis to act in a coordinated spatial arrangement.
SS-31 binds to this lipid. In model membranes, nuclear magnetic resonance showed that the aromatic side chains of dimethyltyrosine and phenylalanine penetrate cardiolipin-containing bilayers. This interaction did not occur in pure phosphatidylcholine membranes. The biochemical study on cardiolipin and cytochrome c describes selective binding to cardiolipin-containing membranes.
Cytochrome c transports electrons between complexes III and IV of the respiratory chain. When bound to cardiolipin, it can also display peroxidase activity. SS-31 inhibited this activity in biochemical experiments and promoted the reduction of cardiolipin-bound cytochrome c by ascorbate or glutathione.
A retained coordination between the heme iron and the methionine residue Met80 was proposed as an explanation for the lower peroxidase activity. The study on cardiolipin binding and ischemic mitochondria links this finding to improved electron transfer at the mitochondrial membrane.
In isolated mitochondria, SS-31 increased substrate- and ADP-supported respiration in State 3. At the same time, ATP production and the P/O ratio rose, while respiration in State 4 remained unchanged. State 3 denotes ADP-supported respiration; State 4 denotes respiration after ADP consumption.
A higher P/O ratio means more ATP formed per oxygen consumed and thus more efficient coupling of electron transport and phosphorylation. The measurements show this improved coupling in the isolated system; a clinical benefit does not automatically follow from it.
The MMPOWER-3 trial tested elamipretide in 218 people with primary mitochondrial myopathy over 24 weeks. The randomized, double-blind phase 3 trial missed both primary endpoints: neither the six-minute walk distance nor the prespecified fatigue measure improved significantly compared with placebo. This result applies to the patient group studied and cannot be transferred to other mitochondrial diseases.
Separate from this is the FDA's accelerated approval of Forzinity (elamipretide) in September 2025 for improving muscle strength in people with Barth syndrome and a body weight of at least 30 kg. The basis was knee extensor strength as a surrogate marker likely to predict a benefit; the FDA required a confirmatory placebo-controlled trial. The approval applies to this specific formulation and indication, not to SS-31 research material in general. The FDA announcement on the accelerated approval documents the decision and the required confirmatory trial.
SS-31 is available in 10 mg and 50 mg variants. The milligram figures indicate the amount per vial, not the concentration. Anyone who wants to study cardiolipin and the organization of the respiratory chain can now buy SS-31 and choose the variant that suits the research project.
No reviews yet. Be the first to share your experience.
Research Use Only (RUO)
Tier II · In-process
Batch · final
Identity, purity, and assay before release.
Tier III · Third-party lab
Tier III · Third-party lab
External · independent
HPLC, ICP-MS, and microbiology by accredited lab.
Every batch is analyzed by an independent laboratory via HPLC before shipment. We document purity (avg. 99.41% in 2026), mass spectrometry identity, and sterility. Production follows GMP standards in ISO-certified laboratories.
SS-31 is an aromatic-cationic tetrapeptide with the four residues D-Arg, dimethylTyr, Lys and Phe. The C-terminus is amidated, the sequence is D-Arg-dimethylTyr-Lys-Phe-NH2, and the reported net charge is +3.
Cardiolipin is an anionic lipid of the inner mitochondrial membrane and is important for cristae structure and the organization of the respiratory chain. SS-31 binds to it; in model membranes, its aromatic side chains selectively penetrate cardiolipin-containing bilayers.
In the randomized, double-blind phase 3 trial with 218 people with primary mitochondrial myopathy, the six-minute walk distance and the fatigue measure did not improve significantly compared with placebo after 24 weeks. Both primary endpoints were therefore not met.
No. It is limited to Forzinity (elamipretide), the Barth syndrome indication and people weighing at least 30 kg. It does not automatically apply to other SS-31 formulations or research materials.